|
Q3 FY2026
As of Apr 30, 2026
|
Q2 FY2026
As of Jan 31, 2026
|
Q1 FY2026
As of Oct 31, 2025
|
Q4 FY2025
As of Jul 31, 2025
|
Q3 FY2025
As of Apr 30, 2025
|
Q2 FY2025
As of Jan 31, 2025
|
Q1 FY2025
As of Oct 31, 2024
|
Q4 FY2024
As of Jul 31, 2024
|
Q3 FY2024
As of Apr 30, 2024
|
Q2 FY2024
As of Jan 31, 2024
|
Q1 FY2024
As of Oct 31, 2023
|
Q4 FY2023
As of Jul 31, 2023
|
Q3 FY2023
As of Apr 30, 2023
|
Q2 FY2023
As of Jan 31, 2023
|
Q1 FY2023
As of Oct 31, 2022
|
Q4 FY2022
As of Jul 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||
| CURRENT ASSETS: | ||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||
| Amounts receivable | ||||||||||||||||
| Prepaid expenses | ||||||||||||||||
| Short-term investments | ||||||||||||||||
| Amounts receivable and prepaid expenses | ||||||||||||||||
| Total current assets | ||||||||||||||||
| NON-CURRENT ASSETS: | ||||||||||||||||
| Investments | ||||||||||||||||
| Equity investment in BC Therapeutics | ||||||||||||||||
| Intangible assets, net | ||||||||||||||||
| Property and equipment, net | ||||||||||||||||
| Long term prepaid expenses | ||||||||||||||||
| Total non-current assets | ||||||||||||||||
| Total assets | ||||||||||||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||||||||||
| CURRENT LIABILITIES: | ||||||||||||||||
| Trade payables | ||||||||||||||||
| Accrued expenses and other payables | ||||||||||||||||
| Total current liabilities | ||||||||||||||||
| NON-CURRENT LIABILITIES: | ||||||||||||||||
| Warrant liability | ||||||||||||||||
| Total non-current liabilities | ||||||||||||||||
| SHAREHOLDERS’ EQUITY: | ||||||||||||||||
| Share Capital of no par value – Authorized: unlimited at April 30, 2026 and July 31, 2025; Issued and outstanding: 7,250,487 shares at April 30, 2026 and 1,883,906 July 31, 2025, respectively | ||||||||||||||||
| Additional paid in capital | ||||||||||||||||
| Share-based payment reserved | ||||||||||||||||
| Warrant reserve | ||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||
| Non-controlling interest | ||||||||||||||||
| Accumulated deficit | ||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||
| Total liabilities and shareholders’ equity |
Loading...
